The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Pfizer's earlier buy-in only gave it ex-US rights to rimegepant, already approved and on sale in the US as Nurtec ODT, so taking control of the entire company will give it full ownership of the ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Ubrelvy (ubrogepant) and Nurtec ODT (rimegepant) are brand-name oral tablets. They’re both prescribed for treating migraine in adults. This article explains the main similarities and differences ...

So were other acquired drugs, especially Nurtec ODT. Pfizer's cost-cutting efforts also paid off, with adjusted diluted earnings per share soaring more than 6x. Sure, Pfizer still faces patent ...

Pfizer Inc. agreed to pay over $59,746,277 ... Biohaven developed, distributed, marketed, and sold the drug Nurtec ODT, a quick-dissolve tablet used to treat and prevent migraines.

Pfizer has agreed to pay $59,746,277.54 ... and honoraria payments to health care providers to encourage them to prescribe Nurtec ODT (Nurtec), a prescription medication for migraine treatment.

Nurtec ODT/Vydura sales jumped 39% to $392 million ... and Abrysvo RSV vaccine sales slumped 62% to $198 million. Guidance: Pfizer reaffirms 2025 revenues of $61 billion-$64 billion compared ...

Analysts on Wall Street project that Pfizer (PFE) will announce quarterly ... Revenue- Primary Care- Nurtec ODT/Vydura- Worldwide' should come in at $384.55 million. The estimate suggests a ...

Pfizer's Q4 adjusted EPS was $0.63 ... This was primarily driven by legacy Seagen, Vyndaqel family, Eliquis, Nurtec ODT/Vydura, and Xtandi, partially offset by lower revenues for Abrysvo, Xeljanz ...